These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 37814829)

  • 21. Clinical and bacteriological outcomes in hospitalised patients with community-acquired pneumonia treated with azithromycin plus ceftriaxone, or ceftriaxone plus clarithromycin or erythromycin: a prospective, randomised, multicentre study.
    Tamm M; Todisco T; Feldman C; Garbino J; Blasi F; Hogan P; de Caprariis PJ; Hoepelman IM
    Clin Microbiol Infect; 2007 Feb; 13(2):162-171. PubMed ID: 17328728
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antibiotic treatment outcomes in community-acquired pneumonia.
    Çilli A; Sayıner A; Çelenk B; Şakar Coşkun A; Kılınç O; Hazar A; Aktaş Samur A; Taşbakan S; Waterer GW; Havlucu Y; Kılıç Ö; Tokgöz F; Bilge U
    Turk J Med Sci; 2018 Aug; 48(4):730-736. PubMed ID: 30119147
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Diagnosis and management of community-acquired pneumonia in adults.
    Watkins RR; Lemonovich TL
    Am Fam Physician; 2011 Jun; 83(11):1299-306. PubMed ID: 21661712
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Fluoroquinolones or macrolides alone versus combined with β-lactams for adults with community-acquired pneumonia: Systematic review and meta-analysis.
    Raz-Pasteur A; Shasha D; Paul M
    Int J Antimicrob Agents; 2015 Sep; 46(3):242-8. PubMed ID: 26092096
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Atypical coverage in community-acquired pneumonia after outpatient beta-lactam monotherapy.
    van Werkhoven CH; van de Garde EMW; Oosterheert JJ; Postma DF; Bonten MJM
    Respir Med; 2017 Aug; 129():145-151. PubMed ID: 28732822
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Azithromycin is not associated with QT prolongation in hospitalized patients with community-acquired pneumonia.
    Goldstein LH; Gabin A; Fawaz A; Freedberg NA; Schwartz N; Elias M; Saliba W
    Pharmacoepidemiol Drug Saf; 2015 Oct; 24(10):1042-8. PubMed ID: 26238864
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of Intravenous Azithromycin on the QT Interval of ICU Patients.
    Oberlander SR; Wall GC
    J Pharm Pract; 2024 Oct; 37(5):1055-1060. PubMed ID: 37939272
    [No Abstract]   [Full Text] [Related]  

  • 28. Discontinuing β-lactam treatment after 3 days for patients with community-acquired pneumonia in non-critical care wards (PTC): a double-blind, randomised, placebo-controlled, non-inferiority trial.
    Dinh A; Ropers J; Duran C; Davido B; Deconinck L; Matt M; Senard O; Lagrange A; Makhloufi S; Mellon G; de Lastours V; Bouchand F; Mathieu E; Kahn JE; Rouveix E; Grenet J; Dumoulin J; Chinet T; Pépin M; Delcey V; Diamantis S; Benhamou D; Vitrat V; Dombret MC; Renaud B; Perronne C; Claessens YE; Labarère J; Bedos JP; Aegerter P; Crémieux AC;
    Lancet; 2021 Mar; 397(10280):1195-1203. PubMed ID: 33773631
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Beta-Lactam Plus Macrolide for Patients Hospitalized With Community-Acquired Pneumonia: Difference Between Autumn and Spring.
    Kim Y; Jeon Y; Kwon KT; Bae S; Hwang S; Chang HH; Kim SW; Lee WK; Yang KH; Shin JH; Shim EK
    J Korean Med Sci; 2022 Nov; 37(45):e324. PubMed ID: 36413797
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Is azithromycin the first-choice macrolide for treatment of community-acquired pneumonia?
    Sánchez F; Mensa J; Martínez JA; García E; Marco F; González J; Marcos MA; Soriano A; Torres A
    Clin Infect Dis; 2003 May; 36(10):1239-45. PubMed ID: 12746768
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Survival benefit associated with clarithromycin in severe community-acquired pneumonia: A matched comparator study.
    Kyriazopoulou E; Sinapidis D; Halvatzis S; Velissaris D; Alexiou N; Kosmas V; Adami ME; Kyprianou M; Kyprianou A; Stefos A; Lada M; Koutoukas P; Pavlaki M; Kyriakoudi A; Makina A; Gogos C; Niederman MS; Giamarellos-Bourboulis EJ
    Int J Antimicrob Agents; 2020 Jan; 55(1):105836. PubMed ID: 31704213
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Narrow-spectrum ß-lactam monotherapy in hospital treatment of community-acquired pneumonia: a register-based cohort study.
    Rhedin S; Galanis I; Granath F; Ternhag A; Hedlund J; Spindler C; Naucler P
    Clin Microbiol Infect; 2017 Apr; 23(4):247-252. PubMed ID: 28017793
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Utilization of broad- versus narrow-spectrum antibiotics for the treatment of outpatient community-acquired pneumonia among adults in the United States.
    Nickel KB; Durkin MJ; Olsen MA; Sahrmann JM; Neuner E; O'Neil CA; Butler AM;
    Pharmacoepidemiol Drug Saf; 2024 Apr; 33(4):e5779. PubMed ID: 38511244
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of beta-lactam and macrolide combination therapy versus fluoroquinolone monotherapy in hospitalized Veterans Affairs patients with community-acquired pneumonia.
    Lodise TP; Kwa A; Cosler L; Gupta R; Smith RP
    Antimicrob Agents Chemother; 2007 Nov; 51(11):3977-82. PubMed ID: 17709460
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prognostic factors in hospitalized community-acquired pneumonia: a retrospective study of a prospective observational cohort.
    Ito A; Ishida T; Tokumasu H; Washio Y; Yamazaki A; Ito Y; Tachibana H
    BMC Pulm Med; 2017 May; 17(1):78. PubMed ID: 28464807
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of antibiotic therapy in severe community-acquired pneumonia: Data from the Infauci study.
    Pereira JM; Gonçalves-Pereira J; Ribeiro O; Baptista JP; Froes F; Paiva JA
    J Crit Care; 2018 Feb; 43():183-189. PubMed ID: 28915392
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparative effectiveness of empiric β-lactam monotherapy and β-lactam-macrolide combination therapy in children hospitalized with community-acquired pneumonia.
    Ambroggio L; Taylor JA; Tabb LP; Newschaffer CJ; Evans AA; Shah SS
    J Pediatr; 2012 Dec; 161(6):1097-103. PubMed ID: 22901738
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Azithromycin monotherapy for patients hospitalized with community-acquired pneumonia: a 31/2-year experience from a veterans affairs hospital.
    Feldman RB; Rhew DC; Wong JY; Charles RA; Goetz MB;
    Arch Intern Med; 2003 Jul; 163(14):1718-26. PubMed ID: 12885688
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of Combined β-Lactam/Macrolide Therapy on Mortality According to the Microbial Etiology and Inflammatory Status of Patients With Community-Acquired Pneumonia.
    Ceccato A; Cilloniz C; Martin-Loeches I; Ranzani OT; Gabarrus A; Bueno L; Garcia-Vidal C; Ferrer M; Niederman MS; Torres A
    Chest; 2019 Apr; 155(4):795-804. PubMed ID: 30471269
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The order of administration of macrolides and beta-lactams may impact the outcomes of hospitalized patients with community-acquired pneumonia: results from the community-acquired pneumonia organization.
    Peyrani P; Wiemken TL; Metersky ML; Arnold FW; Mattingly WA; Feldman C; Cavallazzi R; Fernandez-Botran R; Bordon J; Ramirez JA
    Infect Dis (Lond); 2018 Jan; 50(1):13-20. PubMed ID: 28699429
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.